Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
about
Advances in Cancer Immunotherapy in Solid TumorsHepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for TreatmentEvidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckImmunotherapy in head and neck cancer: aiming at EXTREME precision.Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectivesMetastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report.PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma.Optimizing tumor immune response through combination of radiation and immunotherapy.Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidenceHead and Neck Carcinoma Immunotherapy: Facts and Hopes.Psychosocial Issues in Patients with Head and Neck Cancer: an Updated Review with a Focus on Clinical Interventions.Multiparametric immune profiling in HPV- oral squamous cell cancerImmunotherapy for head and neck cancer: the future of treatment?Genomic sequencing and precision medicine in head and neck cancers.Evaluation of dosing strategy for pembrolizumab for oncology indications.Current studies of immunotherapy in head and neck cancer.Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer.Current insights into the aetiology, pathobiology, and management of local disease recurrence in squamous cell carcinoma of the vulva.Mechanistic and pharmacologic insights on immune checkpoint inhibitors.Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response.Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients.Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.A Review of Immune Therapy in Cancer and a Question: Can Thermal Therapy Increase Tumor Response?HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers.Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.mTOR co-targeting strategies for head and neck cancer therapyResponse assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond.Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.Head and neck cancer in 2016: A watershed year for improvements in treatment?Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
P2860
Q28080113-07E18624-DA9B-4C9B-BFA8-58421A0CD6F8Q33607965-BAE0E740-5967-47EC-8566-3A73DFB14AEDQ33650470-30AC7CAB-B05E-41CC-9619-0919ADC71936Q33756244-308F5CC3-921B-476E-BF45-D13D3BF3398BQ33803297-DE81C412-C20D-42EC-A616-E95DBC3CE96AQ33884361-9D2378E1-8599-473E-9C70-A0CD239CD8E8Q37622998-4217BA7B-4795-4C1C-A37D-80D7DC533A72Q37623044-CD64160F-63F1-4DCE-8E4C-2C31520A069AQ38614781-7B9374AC-F51A-473A-9617-4FDF5DB728E0Q38629357-9E575864-6041-4AC6-87F7-0B9EA41B5A64Q38635035-CA0FCD52-C2A4-4D64-813A-A9482195746FQ38649562-559F478B-9A72-45A6-BD25-9D6C0553531CQ38650710-20E763DB-7C34-4467-AA28-AF9C60EBC882Q38654727-B5EDE9CF-97E8-4E0A-8AF1-F07F4AC9288CQ38671420-38BD03AB-DAFA-49F7-AC0E-BBE7C21CD6CAQ38736238-497F51B9-3A32-46E6-8EF9-BF4A34C01928Q38776454-3D0E1EDD-8569-4798-97AB-AA4882C60059Q38779793-56160E4A-2A58-4ADA-88EF-C2662DA88D80Q38808580-BC317A00-4E6D-4ED0-A453-5346BCE37905Q38818008-1851843D-6374-4C53-AD8B-FC8B1F89DC61Q38851114-B59708B5-2891-4CE8-8CFC-9263610338D4Q39013253-41A58552-02A5-4420-BAFC-189F27F65FE9Q39015086-5B8ECE54-F2B2-4822-ABAB-3F478A11B2A4Q39084115-2FBD3799-7B54-4614-AADA-AD85413EF277Q39190066-3EDF4D61-F127-45E4-9E04-7FDA8D4B56EFQ39193035-3DD41E4E-D780-4888-B833-1CBFBCD836ADQ39194722-B6D1912A-93C6-448F-95FC-640AE7AADE05Q39210287-74F30F47-AE02-4134-80A2-26BB94688E85Q40208391-6135D9F1-2F31-499A-81E8-4DB605AA6FB7Q41633683-6B2394F5-BE99-4D23-BD9E-C73D4D878912Q41886564-100A5D6B-A40A-410E-B3E5-A97852CB5C00Q41928232-4A22EE65-7668-4DFC-9AC1-93922255443AQ41934319-54225D7C-2074-4412-A790-02063BF84053Q42023824-2CB9EC9B-12C3-4740-BA4B-44883862FD8FQ42363764-41C22402-D52D-45B1-809D-BD651854DAB2Q43234029-E3191F8E-249B-42E7-9DE6-9E7535146238Q45933560-32F7FE14-019E-456A-9874-BCA2A6575ABAQ45936626-230CE8ED-25A2-490C-8D53-5439DDEDD928Q46048688-A31A35E8-C354-4112-8728-BFB4C74E85FFQ46129475-39AD27FE-7D54-4D28-BB89-01E2CBCD74E5
P2860
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Antitumor Activity of Pembroli ...... KEYNOTE-012 Expansion Cohort.
@en
type
label
Antitumor Activity of Pembroli ...... KEYNOTE-012 Expansion Cohort.
@en
prefLabel
Antitumor Activity of Pembroli ...... KEYNOTE-012 Expansion Cohort.
@en
P2093
P356
P1476
Antitumor Activity of Pembroli ...... b KEYNOTE-012 Expansion Cohort
@en
P2093
Amy Meister
Barbara Burtness
Bhumsuk Keam
Chia-Chi Lin
Hyun Cheol Chung
Jared Weiss
Jonathan D Cheng
Joseph Paul Eder
Kumudu Pathiraja
P304
P356
10.1200/JCO.2016.68.1478
P407
P577
2016-09-30T00:00:00Z